Activation of The Metabolic Master Regulator PPARγ - A Potential PIOneering Therapy for Pulmonary Arterial Hypertension.
Translational research is essential to develop reverse-remodeling strategies for the treatment of pulmonary vascular disease, pulmonary hypertension and heart failure via mechanistic in vivo studies using animal models resembling human pulmonary arterial hypertension (PAH), cardiovascular remodeling and progressive right heart failure. Since 2007 peroxisome proliferator-activated receptor γ (PPARγ) agonists have emerged as promising novel, anti-proliferative, anti-inflammatory and insulin-sensitizing, efficient medications for the treatment of PAH. However, early diabetes study results, their subsequent misinterpretations, errors in multiple published review articles, and rumors on potential adverse effects in the literature have dampened enthusiasm to consider pharmacological PPARγ activation for the treatment of cardiovascular diseases, including PAH. Most recently, the thiazolidinedione(TZD)-class PPARγ agonist pioglitazone underwent a clinical revival, especially based on the IRIS study - a randomized controlled trial (RCT) in 3,876 non-diabetic patients status post TIA/ischemic stroke, clinically followed for 4.8 years. Here, we discuss preclinical, basic-translational findings and RCTs related to the beneficial and adverse effects of PPARγ agonists of the TZD-class, with a particular focus on the last 5 years. The objective is a data-driven approach to set the preclinical and clinical study record straight. The convincing recent clinical trial data on the lack of significant toxicity in high risk populations justify the timely conduction of clinical studies in order to achieve "repurposing" or "repositioning" of pioglitazone for the treatment of clinical PAH.